These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 16670135)

  • 1. Brief communication: ramipril markedly improves walking ability in patients with peripheral arterial disease: a randomized trial.
    Ahimastos AA; Lawler A; Reid CM; Blombery PA; Kingwell BA
    Ann Intern Med; 2006 May; 144(9):660-4. PubMed ID: 16670135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of ramipril on walking times and quality of life among patients with peripheral artery disease and intermittent claudication: a randomized controlled trial. Journal of the American Medical Association 2013; 309: 453-460.
    Kurklinsky AK; Levy M
    Vasc Med; 2013 Aug; 18(4):234-6. PubMed ID: 23867841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of ramipril on walking times and quality of life among patients with peripheral artery disease and intermittent claudication: a randomized controlled trial.
    Ahimastos AA; Walker PJ; Askew C; Leicht A; Pappas E; Blombery P; Reid CM; Golledge J; Kingwell BA
    JAMA; 2013 Feb; 309(5):453-60. PubMed ID: 23385271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Summaries for patients. Ramipril improves walking ability in patients with peripheral arterial disease.
    Ann Intern Med; 2006 May; 144(9):I24. PubMed ID: 16670129
    [No Abstract]   [Full Text] [Related]  

  • 5. Randomized clinical trial of angiotensin-converting enzyme inhibitor, ramipril, in patients with intermittent claudication.
    Shahin Y; Cockcroft JR; Chetter IC
    Br J Surg; 2013 Aug; 100(9):1154-63. PubMed ID: 23842829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced arterial stiffness may contribute to angiotensin-converting enzyme inhibitor induced improvements in walking time in peripheral arterial disease patients.
    Ahimastos AA; Dart AM; Lawler A; Blombery PA; Kingwell BA
    J Hypertens; 2008 May; 26(5):1037-42. PubMed ID: 18398348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential vascular mechanisms of ramipril induced increases in walking ability in patients with intermittent claudication.
    Ahimastos AA; Latouche C; Natoli AK; Reddy-luthmoodoo M; Golledge J; Kingwell BA
    Circ Res; 2014 Mar; 114(7):1144-55. PubMed ID: 24397981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of ramipril on renal function in patients with intermittent claudication.
    Hobbs SD; Claridge MW; Wilmink AB; Adam DJ; Thomas ME; Bradbury AW
    Vasc Health Risk Manag; 2008; 4(2):471-5. PubMed ID: 18561523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do angiotensin converting enzyme inhibitors improve walking distance in patients with symptomatic lower limb arterial disease? A systematic review and meta-analysis of randomised controlled trials.
    Shahin Y; Mazari F; Chetter I
    Int J Surg; 2011; 9(3):209-13. PubMed ID: 21195215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ramipril reduces large-artery stiffness in peripheral arterial disease and promotes elastogenic remodeling in cell culture.
    Ahimastos AA; Natoli AK; Lawler A; Blombery PA; Kingwell BA
    Hypertension; 2005 Jun; 45(6):1194-9. PubMed ID: 15897362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Walking economy before and after the onset of claudication pain in patients with peripheral arterial disease.
    Gardner AW; Ritti-Dias RM; Stoner JA; Montgomery PS; Scott KJ; Blevins SM
    J Vasc Surg; 2010 Mar; 51(3):628-33. PubMed ID: 20206808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease.
    O'Donnell ME; Badger SA; Sharif MA; Young IS; Lee B; Soong CV
    J Vasc Surg; 2009 May; 49(5):1226-34. PubMed ID: 19217745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of progenitor cell mobilization with granulocyte-macrophage colony-stimulating factor in patients with peripheral artery disease: a randomized clinical trial.
    Poole J; Mavromatis K; Binongo JN; Khan A; Li Q; Khayata M; Rocco E; Topel M; Zhang X; Brown C; Corriere MA; Murrow J; Sher S; Clement S; Ashraf K; Rashed A; Kabbany T; Neuman R; Morris A; Ali A; Hayek S; Oshinski J; Yoon YS; Waller EK; Quyyumi AA
    JAMA; 2013 Dec; 310(24):2631-9. PubMed ID: 24247554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Ginkgo biloba (EGb 761) on treadmill walking time among adults with peripheral artery disease: a randomized clinical trial.
    Gardner CD; Taylor-Piliae RE; Kiazand A; Nicholus J; Rigby AJ; Farquhar JW
    J Cardiopulm Rehabil Prev; 2008; 28(4):258-65. PubMed ID: 18628657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The novel phosphodiesterase inhibitor NM-702 improves claudication-limited exercise performance in patients with peripheral arterial disease.
    Brass EP; Anthony R; Cobb FR; Koda I; Jiao J; Hiatt WR
    J Am Coll Cardiol; 2006 Dec; 48(12):2539-45. PubMed ID: 17174195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease.
    Ostergren J; Sleight P; Dagenais G; Danisa K; Bosch J; Qilong Y; Yusuf S;
    Eur Heart J; 2004 Jan; 25(1):17-24. PubMed ID: 14683738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peripheral arterial disease symptom subtype and walking impairment.
    Collins TC; Petersen NJ; Suarez-Almazor M
    Vasc Med; 2005 Aug; 10(3):177-83. PubMed ID: 16235770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PoleStriding exercise and vitamin E for management of peripheral vascular disease.
    Collins EG; Edwin Langbein W; Orebaugh C; Bammert C; Hanson K; Reda D; Edwards LC; Littooy FN
    Med Sci Sports Exerc; 2003 Mar; 35(3):384-93. PubMed ID: 12618567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of a long-term exercise program on lower limb mobility, physiological responses, walking performance, and physical activity levels in patients with peripheral arterial disease.
    Crowther RG; Spinks WL; Leicht AS; Sangla K; Quigley F; Golledge J
    J Vasc Surg; 2008 Feb; 47(2):303-9. PubMed ID: 18241753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease.
    Mohler ER; Hiatt WR; Creager MA
    Circulation; 2003 Sep; 108(12):1481-6. PubMed ID: 12952839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.